Studies in Paget's disease and their relevance to oncology

Seminars in Oncology

Volumn 28, Issue 4 SUPPL. 11, 2001, Pages 15-21

  Roodman, G David ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR;

BONE METASTASIS; CANCER PATIENT; CONFERENCE PAPER; CYTOKINE PRODUCTION; DRUG BINDING; DRUG EFFICACY; HUMAN; MULTIPLE MYELOMA; OSTEOCLAST; OSTEOLYSIS; PAGET BONE DISEASE; PRIORITY JOURNAL;

EID: 0034839825     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.25442     Document Type: Conference Paper

References (31)

1. Regulation of the differentiation and function of osteoclasts
2. Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of the bone
3. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton
4. Breast cancer cells interact with osteoblasts to support osteoclast formation
5. Bisphosphonates in the treatment of disorders of mineral metabolism
6. Interleukin-6: A potential autocrine/paracrine factor in Paget's disease of bone
7. Paget's disease and osteoclast biology
8. Osteoclast-like cells formed in long-term human bone marrow cultures express a similar surface phenotype as authentic osteoclasts
9. Interleukin-6, IL-6 receptor and IL-6 nuclear factor gene expression in Paget's disease
10. Human myeloma cells promote the production of interleukin-6 by primary human osteoblasts
11. Acute effects of pamidronate administration on serum levels of interleukin-6 in advanced solid tumour patients with bone metastases and their possible implications in the immunotherapy of cancer with interleukin-2
12. Elevated levels of circulating interleukin-6 and transforming growthfactor-beta 1 in patients with metastatic prostatic carcinoma
13. Enhanced expression of interleukin-6 in bone and serum of metastatic renal cell carcinoma
14. New insights into the role of the microenvironment in multiple myeloma
15. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro
16. Fibroblastic stromal cells express receptor activator ligand of NF-kappa B ligand and support osteoclast differentiation
17. Bone loss: Factors that regulate osteoclast differentiation: An update
18. RANK is the essential signalling receptor for osteoclast differentiation factor in osteoclastogenesis
19. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro
20. Skeletal complications of malignancy
21. Current use of bisphosphonates in oncology
22. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease
23. Paget's disease of the bone: Reduction of disease activity with oral risedronate
24. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer
25. Palliation of painful bone metastases from prostate cancer using sodium etidronate: Results of a randomized prospective double-blind, placebo-controlled study
26. Effect of daily etidronate on the osteolysis of multiple myeloma
27. Markers of bone resorption in patients treated with pamidronate
28. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate
29. Bisphosphonates and the prevention of metastasis: First evidence from preclinical and clinical studies
30. Bisphosphonates and breast carcinoma: Present and future
31. Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D (3) and RANKL